School of Pharmaceutical Sciences, Department of Clinical Analysis, São Paulo State University (UNESP), Rod. Araraquara-Jaú - Km 1, 14800-903 Araraquara, SP, Brazil.
Pharmacology Department, Faculty of Medicine, Universidad Valencia, Av. Blasco Ibáñez 15, 46010 Valencia, Spain.
Biomolecules. 2020 Feb 17;10(2):316. doi: 10.3390/biom10020316.
Antisense oligonucleotides (ASOs) are synthetically prepared short single-stranded deoxynucleotide sequences that have been validated as therapeutic agents and as a valuable tool in molecular driving biology. ASOs can block the expression of specific target genes via complementary hybridization to mRNA. Due to their high specificity and well-known mechanism of action, there has been a growing interest in using them for improving vaccine efficacy. Several studies have shown that ASOs can improve the efficacy of vaccines either by inducing antigen modification such as enhanced expression of immunogenic molecules or by targeting certain components of the host immune system to achieve the desired immune response. However, despite their extended use, some problems such as insufficient stability and low cellular delivery have not been sufficiently resolved to achieve effective and safe ASO-based vaccines. In this review, we analyze the molecular bases and the research that has been conducted to demonstrate the potential use of ASOs in vaccines.
反义寡核苷酸(ASO)是经过验证的治疗药物和分子驱动生物学的有价值工具,它们是合成制备的短单链脱氧核苷酸序列。ASO 通过与 mRNA 互补杂交,可以阻止特定靶基因的表达。由于其高度特异性和众所周知的作用机制,人们越来越感兴趣地将其用于提高疫苗的功效。多项研究表明,ASO 可以通过诱导抗原修饰(如增强免疫原性分子的表达)或靶向宿主免疫系统的某些成分来实现所需的免疫反应,从而提高疫苗的功效。然而,尽管它们被广泛使用,但一些问题,如稳定性不足和细胞内递送效率低,尚未得到充分解决,无法实现有效和安全的基于 ASO 的疫苗。在这篇综述中,我们分析了分子基础和已进行的研究,以证明 ASO 在疫苗中的潜在用途。